Biotech Values

[mcbio]

XENE - 7/1/15 CC notes

1. XENE thinks the P2b OA trial may have failed due to insufficient drug exposure in the knee joints.

2. XENE thinks the drug may work better in a neuropathic setting such as the ongoing PHN trial as opposed to nociceptive setting due to ability to obtain a high local concentration.

3. XENE will be looking at patients with 1150W genotype (patients may be more susceptible to pain) as a sub-set in the PHN trial that reads out 2H16.